Altered expression of antithrombotic molecules in human glioma vessels

Isaka, Toshihiko; Yoshimine, Toshiki; Maruno, Motohiko; Kuroda, R.; Ishii, Hidemi; Hayakawa, Tõru

doi:10.1007/s004010050059

Cited by 7 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our previous study demonstrated that the endothelial cells of tumour blood vessels in gliomas express thrombomodulin, while those of the normal brain lack this antithrombotic molecule [7,12]. The present study demonstrated that the tumour blood vessels express TNF-BS, while those of the normal brain do not.…”

Section: Discussionsupporting

confidence: 59%

Cellular targets of exogenous tumour necrosis factor-alpha (TNF?) in human gliomas

et al. 1996

View full text Add to dashboard Cite

To identify the cellular targets of TNF alpha in human gliomas, a total of 30 surgical specimens (12 glioblastomas, 4 anaplastic astrocytomas, 3 astrocytomas, 7 brains adjacent to tumour (BAT), 4 histologically normal-appearing brains) were examined by in vitro binding technique using biotinylated TNF alpha. The TNF-binding sites (TNF-BS) were recognized in the tumour cells in 8 of the 12 glioblastomas, 3 of the 4 anaplastic astrocytomas and in all the 3 astrocytomas. The TNF-BS were also recognized in the vascular endothelial cells in all these cases. The presence of TNF-BS in blood vessels ranged from 7.7 to 74.4% of the background vessels. This wide range of variation in the presence of TNF-BS within the tumour cells and tumour blood vessels may be relevant to the variable response of individual tumours to TNF alpha therapy. Since the tissue of normal brain, which lacks TNF-BS, might hardly be affected by this cytokine, administration of TNF alpha may be considered as an adjuvant therapy in selected groups of patients.

show abstract

Section: Discussionsupporting

confidence: 59%

Cellular targets of exogenous tumour necrosis factor-alpha (TNF?) in human gliomas

et al. 1996

View full text Add to dashboard Cite

show abstract

“…However, in the central nervous system the immunoreactivity to thrombomodulin was reported to be negative in normal cerebral vessels, but moderately to strongly expressed in anaplastic astrocytomas as well as in gliotic brains [9,10]. This study has demonstrated an increased vascular expression of thrombomodulin also in traumatically altered brain tissue.…”

Section: Discussionmentioning

confidence: 47%

The time course of the vascular response to human brain injury - an immunohistochemical study

Hausmann

Betz

2000

International Journal of Legal Medicine

View full text Add to dashboard Cite

In a total of 104 individuals who had sustained traumatic brain injury (TBI), the time-dependent vascular response was investigated at the injured cortical area during the first 30 weeks after the trauma. The immunohistochemical staining of the cerebral blood vessels was performed with antibodies against laminin, type IV collagen, tenascin, thrombomodulin and factor VIII associated antigen. Compared to the immunoreactivity in unaltered control tissue, a significantly increased vascular expression could be detected in cortical contusions after a postinfliction interval of at least 3 h for factor VIII, after 1.6 days for tenascin or after 6.8 days for thrombomodulin, whereas the immunostaining for laminin and type IV collagen was regularly positive even in the vascular endothelium of uninjured brain tissue.

show abstract

“…Thus, the tendency for intratumoral bleeding can not be explained solely by the increased expression of TM. A number of factors compromised in the regulation of thrombotic and antithrombotic activity of blood vessels should be considered [7].…”

Section: Discussionmentioning

confidence: 99%

“…Although our previous study demonstrated increased expression of this antithrombotic protein in the tumor blood vessels of malignant tumors, its significance in the tendency of those tumors to bleed was not clear [7]. In the present study, we investigate the altered expression of TM in the astrocytic tumors of various malignancy and in other non-neoplastic situations of the brain to elucidate its pathophysiological implications.…”

Section: Introductionmentioning

confidence: 88%

Expression of thrombomodulin in astrocytomas of various malignancy and in gliotic and normal brains

et al. 1994

Self Cite

View full text Add to dashboard Cite

A total of 22 surgical specimens, 16 astrocytomas with various malignancy, 3 brains adjacent to tumor and 3 brains with non-neoplastic lesion, was investigated immunohistochemically for the expression of thrombomodulin (TM). This membrane protein is localized on the vascular endothelium of nearly every human tissue and plays a crucial role in the maintenance of antithrombotic property of the endothelial cells. Although the normal cerebral vessels were negative for TM, the tumor vessels were positive for TM. The increased expression of TM was, however, demonstrated not only in glioblastomas but also in low-grade astrocytomas. Furthermore, the vessels in the brains adjacent to tumor and gliotic brains were also positive for TM. Those observations suggested that the tendency of intratumoral bleeding, which is rather characteristic of glioblastomas, is not simply explained by the altered expression of vascular endothelial TM. In two cases of glioblastoma, not only the blood vessels but also the tumor cells were positive. Considering the mitogenic activity of thrombin, a ligand for TM, the increased expression of TM might be related to the tumor neovascularization and also the tumor growth.

show abstract

Altered expression of antithrombotic molecules in human glioma vessels

Cited by 7 publications

References 0 publications

Cellular targets of exogenous tumour necrosis factor-alpha (TNF?) in human gliomas

Cellular targets of exogenous tumour necrosis factor-alpha (TNF?) in human gliomas

The time course of the vascular response to human brain injury - an immunohistochemical study

Expression of thrombomodulin in astrocytomas of various malignancy and in gliotic and normal brains

Contact Info

Product

Resources

About